This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

VaxGen Stockholder Vote Insufficient To Approve Merger With OXiGENE

SOUTH SAN FRANCISCO, Calif., Feb. 4 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN) announced preliminary results of the vote from its special stockholder meeting held on February 3, 2010.

(Logo:  http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)

VaxGen stockholders voted on two proposals. The first proposal, to approve and adopt the Agreement and Plan of Merger among OXiGENE, VaxGen, a wholly-owned subsidiary of OXiGENE, and James P. Panek as the VaxGen stockholder representative, was not approved. 13,229,539 shares voted FOR the merger, 9,492,159 shares voted AGAINST and 26,176 ABSTAINED. The approval of a majority of the Company's total outstanding shares was required to approve the merger. Therefore, a FOR vote totaling 16,553,263 shares was required to approve the merger.

The second proposal, to adjourn the special meeting if necessary, to solicit additional proxies if there were not sufficient votes in favor of the merger, was approved, with approximately 57.7% of the shares voted FOR and 42.3% AGAINST. This proposal needed only a majority of the votes cast to be approved. However, under the terms of the merger agreement, VaxGen was not permitted to adjourn or postpone the meeting without the prior consent of OXiGENE. Prior to the meeting, and based on this anticipated vote result, VaxGen requested OXiGENE's consent to adjourn the meeting to allow additional time to solicit proxies. The OXiGENE board of directors declined to provide OXiGENE's consent to the requested adjournment.

"We are obviously very disappointed that the proposed merger with OXiGENE did not receive the votes necessary for approval," said James P. Panek, VaxGen President. "We achieved substantial support for the merger from our stockholders, with approximately 58% of the shares voted in favor of the merger, representing 40% of the Company's total outstanding shares. However, more than 31% of the outstanding shares were not voted. We believe that with additional time, there was a reasonable likelihood that we could have achieved the necessary vote. We are disappointed that the OXiGENE board was unwilling to consent to an adjournment of our meeting to solicit these un-voted shares."

The VaxGen Board of Directors intends to immediately assess the Company's strategic alternatives.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG
AAPL $128.88 -0.05%
FB $78.92 -0.08%
GOOG $541.35 0.64%
TSLA $231.28 2.30%
YHOO $41.93 -1.40%

Markets

DOW 18,093.59 +69.53 0.39%
S&P 500 2,117.02 +8.73 0.41%
NASDAQ 5,025.2060 +19.8150 0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs